GleamWall
中文EN

TELA TELA Bio, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1561921 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.5%
TTM net income YoY8.3%
TTM EPS YoY41.5%
Revenue 3-yr CAGR21.5%
Net income 3-yr CAGR—

Margins

Gross margin67.3%
Operating margin-41.8%
Net margin-49.3%
FCF margin-37.4%
EBITDA margin-41.1%

Returns

ROE-616.6%
ROA-54.2%
ROIC (approx.)-192.9%
Asset turnover1.10x

Leverage & solvency

Liabilities / assets107.4%
Debt / equity—
Current ratio3.61x
Interest coverage-5.56x

Cash quality & payout

Operating cash flow / net income0.74x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue0.7%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$18.96M$19.29M$19.06M$20.87M$20.69M$20.20M$18.52M$17.65M
Cost of revenue$6.56M$5.25M$6.44M$7.02M$6.62M$6.00M$5.91M$6.33M
Gross profit$12.31M$13.94M$12.52M$13.76M$13.97M$14.11M$12.51M$11.22M
R&D expense$1.60M$2.72M$2.34M$2.13M$2.35M$2.20M$2.54M$2.03M
SG&A expense$3.00M$4.06M$4.17M$3.78M$3.95M$4.13M$3.84M$3.59M
Operating income-$7.29M-$9.28M-$10.53M-$6.65M-$7.55M-$9.08M-$10.47M-$8.35M
Interest expense$2.10M$2.08M$2.05M$1.64M$1.20M$1.19M$1.22M$1.28M
Pretax income-$9.20M-$11.20M-$12.21M-$8.90M-$8.60M-$9.89M-$11.21M-$9.35M
Income tax$103,000$60,000$60,000$145,000$0$33,000$52,000—
Net income-$9.30M-$11.26M-$12.27M-$9.04M-$8.60M-$9.92M-$11.26M-$9.21M
EBITDA-$7.12M-$9.11M-$10.36M-$6.52M-$7.40M-$8.91M-$10.30M-$8.18M
EPS (basic)-0.16-0.20-0.21—-0.19-0.22-0.25—
EPS (diluted)-0.16-0.20-0.21—-0.19-0.22-0.25—
Weighted avg. shares (diluted)57.69M57.41M57.26M—45.42M45.37M45.27M—
Balance sheet
Cash & equivalents$22.66M$30.42M$39.54M$50.84M$29.71M$34.98M$42.83M$52.94M
Receivables$9.27M$9.64M$9.71M$10.35M$11.27M$11.24M$10.56M$10.10M
Inventory$11.61M$11.06M$12.21M$11.02M$11.56M$11.37M$13.53M$12.78M
Current assets$44.60M$54.49M$64.30M$75.58M$56.05M$60.74M$69.75M$78.07M
PP&E, net$1.88M$2.05M$2.16M$2.23M$2.21M$2.17M$2.20M$2.34M
Intangibles$1.07M$1.17M$1.26M$1.36M$1.45M$1.55M$1.64M$1.74M
Total assets$49.49M$59.74M$69.89M$81.42M$61.59M$67.54M$77.25M$86.57M
Current liabilities$72.86M$18.22M$17.83M$17.98M$16.98M$19.06M$16.54M$15.60M
Short-term debt$56.30M————$3.33M——
Long-term debt—$56.08M$55.87M$55.65M$41.49M$38.05M$41.27M$41.12M
Total debt—$56.08M$55.87M$55.65M$41.49M$41.38M$41.27M$41.12M
Total liabilities$74.07M$75.60M$75.09M$75.11M$60.03M$58.35M$59.13M$58.11M
Shareholders' equity-$24.58M-$15.87M-$5.20M$6.31M$1.56M$9.18M$18.12M$28.46M
Net debt—$25.66M$16.32M$4.81M$11.78M$6.41M-$1.56M-$11.81M
Shares outstanding45.14M44.83M44.77M44.54M40.34M39.58M39.55M39.40M
Cash flow statement
Operating cash flow-$8.69M-$9.38M-$11.17M-$4.87M-$5.72M-$7.91M-$9.72M-$7.53M
Capital expenditure$7,000$59,000$119,000$91,000$211,000$114,000$32,000$264,000
Free cash flow-$8.70M-$9.44M-$11.29M-$4.96M-$5.93M-$8.02M-$9.76M-$7.79M
Investing cash flow$1.02M$239,000$190,000$192,000$312,000$204,000$138,000-$190,000
Financing cash flow-$54,000-$15,000-$298,000$25.84M$24,000-$3,000-$116,000$42.91M
Depreciation & amortization$172,000$171,000$169,000$130,000$153,000$175,000$172,000$171,000
Stock-based compensation$626,000$613,000$816,000$812,000$955,000$985,000$1.04M$1.09M

Free plan shows the latest 8 periods; Pro shows all 33 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.